Whether or Not Use High Does Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

WANG CHangzheng

Corresponding?author：

Keywords：

穩定期; COPD; 聯合治療; 吸入; 激素

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

COPD 被定義為一種慢性肺部“炎癥”性疾病。COPD 的炎癥反應由吸煙、大氣污染等有害顆粒或氣體所誘發, 主要累及小氣道和肺實質, 導致慢性支氣管炎和氣道阻塞; 同時還導致肺實質的破壞, 引起肺氣腫, 形成不完全可逆的氣流受限。COPD 的炎癥以中性粒細胞為主, 肺泡巨噬細胞、CD8 + T細胞以及肥大細胞、嗜酸粒細胞、CD4 + T細胞和B 細胞等都可能參與了COPD 炎癥過程。
糖皮質激素( 簡稱激素) 具有廣泛的抗炎作用, 是臨床最常用的抗炎藥物。激素用于哮喘治療取得了良好的臨床療效。但是在COPD 治療上卻存在許多爭議．．．．．．

Citation： WANG CHangzheng. Whether or Not Use High Does Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease. Chinese Journal of Respiratory and Critical Care Medicine, 2010, 9(3): 228-229. doi: Copy

1.	Sahn SA. Corticosteroids in chronic bronchitis and pulmonary emphysema.Chest. 1978 Mar;73(3):389-96.
2.	van Grunsven PM, van Schayck CP, Derenne JP, et al.Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 1999 Jan;54(1):7-14.
3.	Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.Lancet. 1999;353(9167):1819-23.
4.	Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.N Engl J Med. 1999 ;340(25):1948-53.
5.	The Lung Health Study Research Group.Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease. N Engl J Med 2000;343: 1902–1909.
6.	Burge PS, Calverley PM, Jones PW et al.Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 ;13;320(7245):1297-303.
7.	Hattotuwa KL, Gizycki MJ, Ansari TW, et al.The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165(12):1592-6.
8.	Culpitt SV, Maziak W, Loukidis S, et al.Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1635-9.
9.	Calverley P, Pauwels R, Vestboet J , et al.Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361: 449–56.
10.	Calverley PM, Anderson JA, Celli B,et al, Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007;356:775-89.
11.	Celli BR, Thomas NE, Anderson JA, et al. Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease.Results from the TORCH Study. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8.
12.	Barnes NC, Qiu YS, Pavord ID, et al .Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.Am J Respir Crit Care Med. 2006 Apr 1;173(7):736-43.
13.	Bourbeau J, Christodoulopoulos P, Maltais F, et al..Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007;62(11):938-43.
14.	Perng DW, Tao CW, Su KC, et al. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J. 2009;33(4):778-84.
15.	Cazzola M, Di Lorenzo G, Di Perna F, et al.Additive effects of salmeterol and fluticasone or theophylline in COPD.Chest. 2000 Dec;118(6):1576-81.
16.	Tashkin DP, Rennard SI, Martin P, et al.. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975-2000.
17.	Szafranski W, Cukier A, Ramirez A, et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74-81.
18.	Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.Chest. 2003 Sep;124(3):834-43.
19.	Mortaz E, Rad MV, Johnson M, et al.Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke.J Mol Med. 2008 ;86(9):1045-56.
20.	Sarir H, Mortaz E, Karimi K, et al.Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages.Eur J Pharmacol. 2007;571(1):55-61.
21.	Mortaz E, Rad MV, Johnson M, et al.Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J Mol Med. 2008 September; 86(9): 1045–1056.

1. Sahn SA. Corticosteroids in chronic bronchitis and pulmonary emphysema.Chest. 1978 Mar;73(3):389-96.
2. van Grunsven PM, van Schayck CP, Derenne JP, et al.Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 1999 Jan;54(1):7-14.
3. Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.Lancet. 1999;353(9167):1819-23.
4. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.N Engl J Med. 1999 ;340(25):1948-53.
5. The Lung Health Study Research Group.Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease. N Engl J Med 2000;343: 1902–1909.
6. Burge PS, Calverley PM, Jones PW et al.Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 ;13;320(7245):1297-303.
7. Hattotuwa KL, Gizycki MJ, Ansari TW, et al.The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165(12):1592-6.
8. Culpitt SV, Maziak W, Loukidis S, et al.Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1635-9.
9. Calverley P, Pauwels R, Vestboet J , et al.Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361: 449–56.
10. Calverley PM, Anderson JA, Celli B,et al, Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007;356:775-89.
11. Celli BR, Thomas NE, Anderson JA, et al. Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease.Results from the TORCH Study. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8.
12. Barnes NC, Qiu YS, Pavord ID, et al .Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.Am J Respir Crit Care Med. 2006 Apr 1;173(7):736-43.
13. Bourbeau J, Christodoulopoulos P, Maltais F, et al..Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007;62(11):938-43.
14. Perng DW, Tao CW, Su KC, et al. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J. 2009;33(4):778-84.
15. Cazzola M, Di Lorenzo G, Di Perna F, et al.Additive effects of salmeterol and fluticasone or theophylline in COPD.Chest. 2000 Dec;118(6):1576-81.
16. Tashkin DP, Rennard SI, Martin P, et al.. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975-2000.
17. Szafranski W, Cukier A, Ramirez A, et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74-81.
18. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.Chest. 2003 Sep;124(3):834-43.
19. Mortaz E, Rad MV, Johnson M, et al.Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke.J Mol Med. 2008 ;86(9):1045-56.
20. Sarir H, Mortaz E, Karimi K, et al.Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages.Eur J Pharmacol. 2007;571(1):55-61.
21. Mortaz E, Rad MV, Johnson M, et al.Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J Mol Med. 2008 September; 86(9): 1045–1056.

Chinese Journal of Respiratory and Critical Care Medicine

Whether or Not Use High Does Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease

Abstract Full text Figures/Tables Video References Cited by

Format

Content